173 related articles for article (PubMed ID: 23796729)
1. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study.
Rajzbaum G; Grados F; Evans D; Liu-Leage S; Petto H; Augendre-Ferrante B
Joint Bone Spine; 2014 Jan; 81(1):69-75. PubMed ID: 23796729
[TBL] [Abstract][Full Text] [Related]
2. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS).
Walsh JB; Lems WF; Karras D; Langdahl BL; Ljunggren O; Fahrleitner-Pammer A; Barrett A; Rajzbaum G; Jakob F; Marin F
Calcif Tissue Int; 2012 May; 90(5):373-83. PubMed ID: 22466444
[TBL] [Abstract][Full Text] [Related]
4. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS).
Langdahl BL; Ljunggren Ö; Benhamou CL; Marin F; Kapetanos G; Kocjan T; Lespessailles E; Napoli N; Nikolic T; Petto H; Moll T; Lindh E
Calcif Tissue Int; 2016 Sep; 99(3):259-71. PubMed ID: 27137783
[TBL] [Abstract][Full Text] [Related]
5. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).
Langdahl BL; Rajzbaum G; Jakob F; Karras D; Ljunggren O; Lems WF; Fahrleitner-Pammer A; Walsh JB; Barker C; Kutahov A; Marin F
Calcif Tissue Int; 2009 Dec; 85(6):484-93. PubMed ID: 19823760
[TBL] [Abstract][Full Text] [Related]
6. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS).
Ljunggren O; Benhamou CL; Dekker J; Kapetanos G; Kocjan T; Langdahl BL; Napoli N; Petto H; Nikolić T; Lindh E
Curr Med Res Opin; 2014 Aug; 30(8):1607-16. PubMed ID: 24720366
[TBL] [Abstract][Full Text] [Related]
7. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS).
Napoli N; Langdahl BL; Ljunggren Ö; Lespessailles E; Kapetanos G; Kocjan T; Nikolic T; Eiken P; Petto H; Moll T; Lindh E; Marin F
Calcif Tissue Int; 2018 Oct; 103(4):359-371. PubMed ID: 29909449
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
[TBL] [Abstract][Full Text] [Related]
9. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study.
Jakob F; Oertel H; Langdahl B; Ljunggren O; Barrett A; Karras D; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Barker C; Lems WF; Marin F
Eur J Endocrinol; 2012 Jan; 166(1):87-97. PubMed ID: 22048967
[TBL] [Abstract][Full Text] [Related]
10. Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study.
Ljunggren Ö; Barrett A; Stoykov I; Langdahl BL; Lems WF; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Karras D; Marin F
BMC Musculoskelet Disord; 2013 Aug; 14():251. PubMed ID: 23968239
[TBL] [Abstract][Full Text] [Related]
11. Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO).
Adami S; Maugeri D; Toscano V; Topa G; Carminiti M; Brancati A; Massarotti M; Osella G; Malavolta N; Iolascon G; Cagnoni C; Camozzi V; Corradini C; Nardi A; Migliaccio S; Ulivieri FM; Resmini G; Valle D; Tauchmanovà L; Silvestri S;
Clin Exp Rheumatol; 2011; 29(3):477-84. PubMed ID: 21640043
[TBL] [Abstract][Full Text] [Related]
12. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting.
Rajzbaum G; Jakob F; Karras D; Ljunggren O; Lems WF; Langdahl BL; Fahrleitner-Pammer A; Walsh JB; Gibson A; Tynan AJ; Marin F
Curr Med Res Opin; 2008 Feb; 24(2):377-84. PubMed ID: 18154690
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).
Cunha-Borges JL; Mier GM; Casas N; Medina A; Molina JF; García ML; Oliveria LG; Caselato MS; Cruz AC; Ippolito V; Flórez S
Adv Rheumatol; 2019 Nov; 59(1):46. PubMed ID: 31703737
[TBL] [Abstract][Full Text] [Related]
14. Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS).
Chen CH; Elsalmawy AH; Ish-Shalom S; Lim SJ; Al-Ali NS; Cunha-Borges JL; Yang H; Casas N; Altan L; Moll T; Gurbuz S; Brnabic AJM; Burge RT; Marin F
Curr Med Res Opin; 2019 Jun; 35(6):1041-1049. PubMed ID: 30474449
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS).
Aloumanis K; Kapetanos G; Bartzis N; Drossinos V;
BMC Musculoskelet Disord; 2015 Jun; 16():136. PubMed ID: 26044820
[TBL] [Abstract][Full Text] [Related]
16. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
Nevitt MC; Chen P; Dore RK; Reginster JY; Kiel DP; Zanchetta JR; Glass EV; Krege JH
Osteoporos Int; 2006 Feb; 17(2):273-80. PubMed ID: 16142502
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS).
Chen CH; Elsalmawy AH; Ish-Shalom S; Lim SJ; AlAli NS; Cunha-Borges JL; Yang H; Casas N; Altan L; Belaya Z; Marin F; Moll T; Gurbuz S; Brnabic A; Pavo I; Florez S
Calcif Tissue Int; 2022 Jan; 110(1):74-86. PubMed ID: 34415388
[TBL] [Abstract][Full Text] [Related]
18. Back pain treatment in post-menopausal osteoporosis with vertebral fractures.
Ulivieri FM
Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):21-3. PubMed ID: 18180603
[TBL] [Abstract][Full Text] [Related]
19. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
20. 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women.
Kong M; Zhou C; Zhu K; Zhang Y; Song M; Zhang H; Tu Q; Ma X
Clin Interv Aging; 2019; 14():1693-1703. PubMed ID: 31631990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
